-$0.90 Earnings Per Share Expected for Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) This Quarter

Equities analysts forecast that Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) will post earnings of ($0.90) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Rhythm Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.71) and the lowest estimate coming in at ($1.06). Rhythm Pharmaceuticals posted earnings per share of ($0.74) during the same quarter last year, which indicates a negative year over year growth rate of 21.6%. The firm is expected to announce its next earnings results on Friday, March 13th.

On average, analysts expect that Rhythm Pharmaceuticals will report full-year earnings of ($3.93) per share for the current year, with EPS estimates ranging from ($4.19) to ($3.52). For the next financial year, analysts anticipate that the firm will post earnings of ($3.41) per share, with EPS estimates ranging from ($4.05) to ($3.06). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings data on Friday, November 1st. The company reported ($1.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.02.

RYTM has been the subject of a number of research analyst reports. BidaskClub raised shares of Rhythm Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 22nd. LADENBURG THALM/SH SH reaffirmed a “buy” rating and issued a $43.00 price target on shares of Rhythm Pharmaceuticals in a research note on Monday, September 9th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $34.00 price target on shares of Rhythm Pharmaceuticals in a research note on Monday, July 29th. ValuEngine upgraded shares of Rhythm Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Cowen reiterated a “buy” rating and issued a $40.00 target price on shares of Rhythm Pharmaceuticals in a report on Wednesday, September 25th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $38.80.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. DekaBank Deutsche Girozentrale bought a new stake in shares of Rhythm Pharmaceuticals in the 2nd quarter worth approximately $564,000. Susquehanna International Group LLP bought a new stake in shares of Rhythm Pharmaceuticals in the 2nd quarter worth approximately $328,000. Rice Hall James & Associates LLC raised its holdings in shares of Rhythm Pharmaceuticals by 172.5% in the 2nd quarter. Rice Hall James & Associates LLC now owns 63,217 shares of the company’s stock worth $1,391,000 after purchasing an additional 40,015 shares in the last quarter. Fosun International Ltd raised its holdings in shares of Rhythm Pharmaceuticals by 37.0% in the 2nd quarter. Fosun International Ltd now owns 40,720 shares of the company’s stock worth $883,000 after purchasing an additional 11,000 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Rhythm Pharmaceuticals by 2.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 126,835 shares of the company’s stock worth $2,751,000 after purchasing an additional 3,057 shares in the last quarter. Institutional investors and hedge funds own 90.57% of the company’s stock.

Shares of NASDAQ:RYTM traded up $0.11 during trading on Thursday, reaching $21.50. 126,300 shares of the company’s stock traded hands, compared to its average volume of 174,771. The company has a 50 day moving average of $21.67 and a 200-day moving average of $22.57. The stock has a market capitalization of $943.98 million, a P/E ratio of -9.00 and a beta of 0.63. Rhythm Pharmaceuticals has a 12 month low of $18.00 and a 12 month high of $32.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.78 and a quick ratio of 7.80.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders.

Featured Article: How does a reverse stock split work?

Get a free copy of the Zacks research report on Rhythm Pharmaceuticals (RYTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit